Friday, 16 October 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 21, 2026

Netflix (NFLX) Q4 2025 Earnings Call Transcript

View original at nasdaq.com
Netflix (NFLX) Q4 2025 Earnings Call Transcript Image source: The Motley Fool. Date Tuesday, Jan. 20, 2026 at 4:45 p.m…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • India ranked #2 and #3 for Netflix paid net adds and revenue growth in Q2 2024

    80% confidence
  • Customer satisfaction reached all-time high

    80% confidence
  • Netflix executed 200+ live events

    80% confidence
  • Netflix content cash-to-expense ratio is 1.1x

    80% confidence
  • YouTube surpassed BBC monthly average audience in the UK according to Barb

    80% confidence
  • Approximately one-third of Netflix members have access to TV-based games through client upgrades

    80% confidence
  • 2026 operating margin will be 2.5 points higher excluding M&A expenses

    80% confidence
  • Netflix retention is among the best in the industry

    80% confidence
  • Netflix operates in 12 ad markets

    80% confidence
  • Netflix expects content amortization to increase 10% year-over-year in 2026

    80% confidence
  • Netflix historically expanded operating margin by approximately 2 percentage points annually on average

    80% confidence
  • Netflix primary quality metric reached all-time high in 2025

    80% confidence
  • Q4 2025 churn improved year-over-year

    80% confidence
  • M&A expenses will create half a percentage point drag on operating margin in 2026

    80% confidence
  • Netflix forecasts 2026 revenue of $51 billion, representing 14% year-over-year growth

    80% confidence
  • Netflix ad revenue was 2.5x higher in 2025 compared to prior year

    80% confidence
  • Post-acquisition, 85% of Netflix revenue will come from current core businesses

    80% confidence
  • Theatrical distribution is a business decision that changes with conditions and insights, not a religious principle

    80% confidence
  • Warner Bros. global box office exceeds $4 billion

    80% confidence
  • Netflix will maintain 45-day theatrical window post-Warner Bros. acquisition

    80% confidence
  • Netflix has approximately 7% of addressable consumer and ad spend globally

    80% confidence
  • Sign-up flow optimization generated material revenue wins in Q2 2024

    80% confidence
  • Branded originals viewing grew 9% year-over-year in H2 2025 and 7% in H1 2025, representing approximately 50% of total viewing

    80% confidence
  • Q2 2024 had strong acquisition and healthy retention across all regions

    80% confidence
  • Netflix operating profit grew approximately 30% in 2025

    80% confidence
  • Netflix expects approximately $6 billion in free cash flow for 2026

    80% confidence
  • Japanese consumers watch 50-67% less TV than US consumers

    80% confidence
  • The Warner Bros. deal is pro-consumer, pro-innovation, pro-worker, pro-creator, and pro-growth

    80% confidence
  • Total Netflix view hours grew 2% year-over-year in 2025, adding 1.5 billion hours, accelerating from 1% in prior year

    80% confidence
  • Q2 2024 operating margin expanded 5 percentage points year-over-year

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Netflix (NFLX) Q4 2025 Earnings Call Transcript — Source | Via News | ViaNews EU